The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies
- 1 June 1998
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 24 (3) , 205-220
- https://doi.org/10.1016/s0305-7372(98)90050-0
Abstract
No abstract availableThis publication has 44 references indexed in Scilit:
- Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.Journal of Clinical Oncology, 1997
- Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.Journal of Clinical Oncology, 1997
- Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.Journal of Clinical Oncology, 1996
- Phase II study of topotecan in patients with recurrent malignant gliomaAnnals of Oncology, 1996
- Topotecan in colorectal cancer: A phase II study of the EORTC early clinical trials groupAnnals of Oncology, 1995
- Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group studyAnnals of Oncology, 1995
- Mechanisms of resistance to topoisomerase inhibitorsPublished by Springer Nature ,1994
- Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.Journal of Clinical Oncology, 1993
- CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.Journal of Clinical Oncology, 1992
- A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.Journal of Clinical Oncology, 1992